Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease
Advanced solid tumors responded favorably to the combination of rucaparib plus sacituzumab govitecan, in results of the phase 1B SEASTAR study presented at this year’s virtual European Society for Medical Oncology meeting by Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science; associate professor, Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology; and associate director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center.